Recovery from anthracycline cardiomyopathy after long-term support with a continuous flow left ventricular assist device
- PMID: 19134539
- DOI: 10.1016/j.healun.2008.10.002
Recovery from anthracycline cardiomyopathy after long-term support with a continuous flow left ventricular assist device
Abstract
We report the clinical course of a 16-year-old girl in remission from non-Hodgkin's lymphoma who presented in cardiogenic shock due to a severe anthracycline cardiomyopathy. The patient was initially stabilized using central extracorporeal membrane oxygenation support, followed by conversion to a left ventricular assist device. Unexpected evidence of cardiac recovery 9 months after implant enabled device weaning during a 3-month period, culminating in successful device explantation 1 year after implant. The patient survives 18 months after explant in New York Heart Association class I, on conventional heart failure medical management and metabolic therapy.
Comment in
-
Recovery from anthracycline cardiomyopathy--how can it be explained?J Heart Lung Transplant. 2009 Jul;28(7):751. doi: 10.1016/j.healun.2009.04.001. Epub 2009 May 6. J Heart Lung Transplant. 2009. PMID: 19560709 No abstract available.
Publication types
MeSH terms
Substances
Supplementary concepts
LinkOut - more resources
Full Text Sources
